David M. Lucas PhD

David M. Lucas PhD
Res Asst ProfessorCollege of Medicinelucas.194@osu.edu
455D Comprehensive Cancer Center 410 W 12th Avenue Columbus Ohio 43210
Phone:614-292-8154Fax:
  • Experimental Therapeutics

Current Publications

  • Byrd JCProlonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.Blood 123 1810-7 3/20/2014
  • Jordan CTFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Leukemia 2/28/2014
  • Singh R, Mortazavi A, Telu KH, Nagarajan P, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MRIncreasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.Nucleic Acids Res 41 9284-95 11/1/2013
  • Bueno Pérez L, Pan L, Sass E, Gupta SV, Lehman A, Kinghorn A, Lucas DMPotentiating effect of the flavonolignan (-)-hydnocarpin in combination with vincristine in a sensitive and P-gp-expressing acute lymphoblastic leukemia cell line.Phytother Res 27 1735-8 11/1/2013
  • Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel TTherapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.PLoS One 8(9) e76136 9/26/2013
  • Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52(8) 705-12 8/1/2013
  • Lucas DM, Hertlein E, Lu Y, Sass EJ, Lapalombella RT, Chen TL, Davis M, , Lehman A, Jarjoura D, Byrd JCThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Clin Cancer Res 19(9) 2406-19 5/1/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci GSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 3/16/2013
  • Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JCSelective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.Blood 120(23) 4621-34 11/29/2012
  • Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Baiocchi R, Grever MR, Lucas DMDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Clin Cancer Res 18(17) 4600-11 9/1/2012
  • Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JCER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood 120(6) 1262-73 8/9/2012
  • Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JCQuantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.J Clin Oncol 30(20) 2483-91 7/10/2012
  • Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JCTetraspanin CD37 directly mediates transduction of survival and apoptotic signals.Cancer Cell 21(5) 694-708 5/15/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu